DecisionDx-Melanoma Gene Expression Test Improves Risk Prediction Beyond Standard Staging
Data from nearly 1,900 SEER-linked patients show the test identifies meaningful survival differences within the same AJCC stage.
Category: Melanoma
Melanoma
Latest
Melanoma
Latest
DecisionDx-Melanoma: A New Frontier in Personalized Cancer Care
The test uses gene expression profiling to provide personalized risk assessments, reducing unnecessary SLNB in melanoma patients.
Melanoma
Latest
Castle Biosciences’ Gene Expression Profile Test Effectively Predicts Sentinel Lymph Node Positivity
Castle Biosciences' gene expression profile test for melanoma prognosis efficiently predicted the risk of sentinel lymph node positivity.
DermTech’s Melanoma Assay Gets VHA Recommendation
The U.S. General Services Administration has recommended DermTech’s foundational melanoma assay for coverage by the VHA.
Read More
Biomarkers Predict Resistance to Immunotherapies in Melanoma
Researchers found potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to cause progression of melanoma cells.
Read More
Roche Launches PRAME Antibody for Suspected Melanoma
Roche has announced the launch of the PRAME Antibody to identify PRAME protein expression with suspected melanoma.
Read More
New AI Tech Predicts Diagnostic Concordance For Melanoma, Proscia Says
Proscia released study results on new AI that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.
Read More
Proscia’s AI Selected for Skin Pathology
Unilabs and Proscia have announced that the diagnostic group has chosen Proscia’s DermAI skin pathology solution.
Read More
InterVenn’s Melanoma Test Helps Oncologists Plan for Treatment
InterVenn’s new melanoma test is commercially available as a glycoproteomics LDT that aids oncologists in planning treatment for melanoma.
Read More
New Biomarkers Can Predict Response to Melanoma Immunotherapy Treatment
Researchers have discovered blood biomarkers that can help identify if someone suffering from Melanoma can benefit from immune checkpoint inhibitors.
Read More
Foundation Medicine Receives FDA Approval for its Tissue-Based Genomic Profiling Test
FoundationOne CDx is used as a companion diagnostic for two groups of FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies.
Read More
Virtual Histology Eliminates Need for Invasive Skin Biopsies
Researchers used deep learning framework to transform microscopy images of intact skin into histochemically stained sections imaged on microscope slides.
Read More
AI Breakthrough Announced in Melanoma Detection
Proscia has released study results on new technology that leverages AI to automatically detect melanoma with a high degree of accuracy.
Read More
Castle Biosciences to Acquire Myriad MyPath Laboratory
Castle Biosciences’ acquisition of CLIA-certified Myriad MyPath Laboratory from Myriad Genetics will expand its suite of genomic tests for skin cancer.
Read More
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read MoreBiocare Medical Launches Seven Antibody Markers for Clinical Diagnostic and Cancer Research Applications
The launch focuses on several immunooncology markers that are critical for early-stage cancer drug development and patient treatment.
Read MoreBio-Rad Introduces Anti-Ipilimumab Antibodies
The highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor ipilimumab.
Read More
Interventional Study to Evaluate Multicancer Early Detection Test
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More